高级检索
当前位置: 首页 > 详情页

Potential of alisols as cancer therapeutic agents: Investigating molecular mechanisms, pharmacokinetics and metabolism

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Heilongjiang Univ Chinese Med, Natl Chinmed Res Ctr, Dept Pharmaceut Anal,Metab Lab, State key Lab Integrat & Innovat Class Formula & M, Heping Rd 24, Harbin 150040, Peoples R China [2]Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Ave Wai Long, Taipa, Macao, Peoples R China [3]Guangzhou Univ Chinese Med, Affiliated Hosp 2, State Key Lab Dampness Syndrome, Dade Rd 111, Guangzhou, Peoples R China
出处:
ISSN:

关键词: Alisols Cancer Pharmacokinetics Metabolism Hepatoenteric circulation

摘要:
Albeit remarkable achievements in anti-cancer endeavors, the prevention and treatment of cancer remain unresolved challenges. Hence, there is an urgent need to explore new and efficacious natural compounds with potential anti-cancer therapeutic agents. One such group of compounds is alisols, tetracyclic triterpene alcohols extracted from alisma orientale. Alisols play a significant role in cancer therapy as they can suppress cancer cell proliferation and migration by regulating signaling pathways such as mTOR, Bax/Bcl-2, CHOP, caspase, NF-kB and IRE1. Pharmacokinetic studies showed that alisols can be absorbed entirely, rapidly, and evenly distributed in vivo. Moreover, alisols are low in toxicity and relatively safe to take. Remarkably, each alisol can be converted into many compounds with different pathways to their anti-cancer effects in the body. Thus, alisols are regarded as promising anti-cancer agents with minimal side effects and low drug resistance. This review will examine and discuss alisols' anti-cancer molecular mechanism, pharmacokinetics and metabolism. Based on a comprehensive analysis of nearly 20 years of research, we evaluate the therapeutic potential of alisols for various types of cancer and offer insights and strategies for developing new cancer treatments.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 2 区 医学
小类 | 1 区 药学 2 区 医学:研究与实验
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验 2 区 药学
JCR分区:
出版当年[2021]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Heilongjiang Univ Chinese Med, Natl Chinmed Res Ctr, Dept Pharmaceut Anal,Metab Lab, State key Lab Integrat & Innovat Class Formula & M, Heping Rd 24, Harbin 150040, Peoples R China
通讯作者:
通讯机构: [1]Heilongjiang Univ Chinese Med, Natl Chinmed Res Ctr, Dept Pharmaceut Anal,Metab Lab, State key Lab Integrat & Innovat Class Formula & M, Heping Rd 24, Harbin 150040, Peoples R China [2]Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Ave Wai Long, Taipa, Macao, Peoples R China [3]Guangzhou Univ Chinese Med, Affiliated Hosp 2, State Key Lab Dampness Syndrome, Dade Rd 111, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号